Dr. Tannir on Results With Telaglenastat/Cabozantinib in mRCC

Nazir Tannir, MD, FACP, a professor in the Department of Genitourinary Medical Oncology, Division of Cancer Medicine, and Ransom Horne, Jr. Professorship for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the efficacy of the combination of telaglenastat (CB-839)and cabozantinib (Cabometyx) in patients with metastatic renal cell carcinoma (mRCC), as demonstrated in the phase 2 CANTATA trial (NCT03428217).

The results of the trial, which examined the combination vs placebo plus cabozantinib in patients with mRCC, demonstrated that the addition of telaglenastat did not show an improvement in progression-free survival (PFS) over placebo plus cabozantinib, according to Tannir. The median PFS in both arms was very similar, at 9.2 months in the combination arm vs 9.3 months in the placebo arm. Additionally, the hazard ratio was 0.94, meaning there was no advantage or benefit seen with the addition of telaglenastat, Tannir says. PFS was assessed by independent review and results were consistent with investigator review, Tannir notes.

Moreover, the overall response rate in the combination arm was 31%, compared with 28% in the placebo arm, Tannir adds. Again, these results show there was little difference in responses between the 2 study arms, Tannir concludes.